synergychc.com (SNYR) - Long-Term Debt to Capital Coefficient

Synergy CHC - graphic logo of issuer SNYR

Synergy CHC Corp (SNYR) is increasing the margins of its niche wellness brands through an AI accelerator and influencers. The long-term debt-to-equity trajectory visualizes financial stability, where 0.00 shows the current value of the metric. The holding company is monetizing healthy lifestyle trends by updating vitamin formulations, while consistent plant utilization and the modernization of packaging lines minimize operating expenses.

synergychc.com (SNYR): Long-Term Debt to Equity from 10/24/2024 to 10/03/2026
Signature product of Synergy CHC Corp.

The deployment of robotic systems and RPA bots at Synergy CHC Corp. (SNYR) requires significant capital expenditures, which is reflected in the long-term debt-to-equity ratio. This metric assesses the ratio of liabilities with a maturity of over one year to equity. The indicator measures the degree of financial leverage, determining the business's reliance on borrowed financing. An increase in this figure signals a risk of losing financial stability. Market consensus utilizes this coefficient to evaluate the company's long-term solvency.

Analysis of competing companies

Haleon PLC - Long-Term Liabilities to Equity|Long-Term Debt to Capital KVUE|VRNA (Verona Pharma Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital MENS (Jyong Biotech Ltd)|Long-Term Debt to Capital ligand.com LGND|AMRX - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient PRGO (Perrigo Company PLC)|Alvotech Corp (ALVO) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Liquidia Inc.|GLPG (Galapagos NV) - Long-Term Debt to Capital|Long-Term Debt to Capital anipharmaceuticals.com|Long-Term Debt to Equity Ratio MNKD (MannKind)|AMPH (Amphastar Pharmaceuticals Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Pacira PCRX|ARS Corp (SPRY) - Long-Term Liabilities to Capital|TBPH: Long-Term Debt to Equity Ratio|aquestive.com - Long-Term Loans to Capital Ratio|SCPH: Long-Term Debt to Capital|Tectonic Therapeutic - Long-Term Debt to Capital Coefficient|TNXP (Tonix Pharmaceuticals Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital SXT China SXTC|Long-Term Debt to Equity Eupraxia Pharmaceuticals (EPRX)|BHST (bioharvest.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity eXoZymes EXOZ|Ratio of Long-Term Indebtedness to Capital Oramed (ORMP)|ENTX: Long-Term Debt to Equity Ratio|Long-Term Liabilities to Capital MindWalk Therapeutics|ABVC BioPharma (ABVC) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio CPIX|QNTM (Quantum BioPharma) - Long-Term Debt to Capital|Long-Term Liabilities to Capital FibroGen Inc FGEN|Long-Term Debt to Equity Telomir Pharma (TELO)|RANI (ranitherapeutics.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital RLYB (Rallybio)|Long-Term Indebtedness to Equity Lexaria Bioscience Corp|PULM: Long-Term Debt to Equity Ratio|Long-Term Liabilities to Capital Pheton Holdings Ltd|APM (aptorumgroup.com) - Long-Term Debt to Equity Ratio|Lyra Therapeutics Inc - Long-Term Debt to Capital Coefficient|IBO (Impact BioMedical Inc) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio TNF Pharma (TNFA)|Long-Term Debt to Capital YCBD|PRFX (PainReform Ltd) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital CYTO (Altamira Therapeutics Ltd.)|LIPO - Long-Term Debt to Equity Ratio|OPTN: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient PIRS (pieris.com)|PROC: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Petros Pharmaceuticals Inc|Long-Term Debt to Equity Qilian International Holding Group Limited|Long-Term Liabilities to Capital ACELYRIN Inc. SLRN|Long-Term Debt to Equity TFF Pharmaceuticals (TFFP)